Back to top
more

Catalyst Pharmaceuticals (CPRX)

(Delayed Data from NSDQ)

$14.89 USD

14.89
772,219

+0.21 (1.43%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $14.87 -0.02 (-0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CPRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Catalyst Pharmaceuticals, Inc. [CPRX]

Reports for Purchase

Showing records 381 - 400 ( 417 total )

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 381

05/17/2013

Company Report

Pages: 9

1Q13 Recap - Emerging Late Stage Orphan Drug Company, PT to $2

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 382

05/17/2013

Daily Note

Pages: 3

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 383

04/03/2013

Daily Note

Pages: 3

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 384

03/28/2013

Daily Note

Pages: 3

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 385

03/27/2013

Company Report

Pages: 4

Firdapse Passes First Test

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 386

11/16/2012

Daily Note

Pages: 20

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 50.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 387

11/15/2012

Company Report

Pages: 8

3Q12 Update - Few Surprises

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 388

11/13/2012

Daily Note

Pages: 20

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 50.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 389

11/13/2012

Company Report

Pages: 8

Maintain Buy as CPP-115/Firdapse Always Were the Best Assets

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 390

10/01/2012

Daily Note

Pages: 29

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 75.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 391

09/28/2012

Daily Note

Pages: 4

Resetting the Catalyst Calendar for November 2012.

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 392

09/11/2012

Daily Note

Pages: 16

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 50.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 393

08/27/2012

Company Report

Pages: 20

Transferring Coverage of Catalyst Pharmaceutical Partners

Provider: RODMAN & RENSHAW, CO.

Price: 50.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 394

08/27/2012

Daily Note

Pages: 3

Transferring Coverage of Catalyst Pharmaceutical Partners

Provider: RODMAN & RENSHAW, CO.

Price: 10.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 395

08/24/2012

Industry Report

Pages: 5

BIOTECHNOLOGY BALANCE SHEET

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 396

08/15/2012

Company Report

Pages: 3

Releases FY2Q12 Financial Results

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 397

08/15/2012

Daily Note

Pages: 3

Releases FY2Q12 Financial Results

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 398

08/10/2012

Industry Report

Pages: 5

BIOTECHNOLOGY BALANCE SHEET

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 399

07/19/2012

Company Report

Pages: 4

Discussions with Management -Programs In-line to Ahead of Schedule

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 400

07/19/2012

Daily Note

Pages: 12

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party